PyInvesting

Market research

VBS.AU Vectus Biosystems Limited

AU AUD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
10M
P/E ratio
Not available
Analyst target
Not available
Dividend yield
Not available
Beta
0.29

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Vectus Biosystems Limited is currently in a long term uptrend where the price is trading 14.2% above its 200 day moving average.

From a valuation standpoint, the stock is 538.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1644.5.

Vectus Biosystems Limited's total revenue rose by 22759.1% to $50K since the same quarter in the previous year.

Its net income has dropped by 104.9% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 31.3% to $-692K since the same quarter in the previous year.

Based on the above factors, Vectus Biosystems Limited gets an overall score of 3/5.